Articles dans des revues sans comité de lecture (4)
  1. 1. Andry, G., Awada, A., Flamen, P., Nguyen, T. D., & Lemort, M. (2007). Approche conservatrice dans la prise en charge des tumeurs des voies aéro-digestives supérieures. Bordet news, 80, 12-13.
  2. 2. Awada, A., de Valeriola, D., & Piccart-Gebhart, M. (1998). Wat kunnen we doen aan de toxiciteit van chemotherapeutica. Medi-sphere (Kraainem), 18, 35-38.
  3. 3. Awada, A., de Valeriola, D., Piccart-Gebhart, M., & Hindley, J. (1998). Attitudes à prendre face aux effets secondaires des agents chimiothérapeutiques. Medi-sphere,(79), 35-38.
  4. 4. de Valeriola, D., Awada, A., Piccart-Gebhart, M., & Hindlet, J.-Y. (1997). Tumeurs solides : de nouvelles ressources thérapeutiques. Medi-sphere,(68), 1-4.
    5.   Communications publiées lors de congrès ou colloques nationaux et internationaux (22)
  5. 1. Awada, A., Hendlisz, A., Gil, T., Schwartz, B., Bartholomeus, S., de Valeriola, D., Brendel, E., Haase, C. G., & Piccart-Gebhart, M. (2004). A phase I study of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced, solid tumors. European Journal of Cancer. Vol. 2 (p. 114) 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics(2004).
  6. 2. Piccart-Gebhart, M., Cardoso, F., Di Leo, A., Awada, A., & Gelber, R. (2002). Controversies in adjuvant systemic therapy of breast cancer. Part I: areas of controversy in the adjuvant systemic therapy of endocrine non-responsive breast cancer. ASCO Educational Book (pp. 144-155) ASCO's annual meeting(May 18-21, 2002: Orlando).
  7. 3. Awada, A., Dubuisson, M., Sales, F., Vereecken, P., Gil, T., Cutler, D. L., Moerman, C., Branle, F., Lehmann, F., Klastersky, J., de Valeriola, D., & Piccart-Gebhart, M. (2002). A phase I study of a prolonged schedule of temozolimide (Temodal (R)) plus liposomal doxorubicin (Caelyx (R)) in advanced solid cancers: Final results of a promising combination. Proceedings of the American Society of Clinical Oncology. Vol. 21 (p. 79) (2001).
  8. 4. Awada, A., Hendlisz, A., Gil, T., Munoz Bermeo, R. A., Bartholomeus, S., de Valeriola, D., van der Auwera, J., Coppieters, S., Moeller, J., & Piccart-Gebhart, M. (2002). Final results of a clinical and pharmacokinetic (PK) phase I study of the Raf kinase inhibitor BAY 43-9006 in refractory solid cancers: A promising anti-tumor agent. European Journal of Cancer. Vol. 38 (p. 52) (2002).
  9. 5. Awada, A., Hendlisz, A., Gil, T., Bleiberg, H., Bartholomeus, S., de Valeriola, D., Dewitte, M., Coppieters, S., Moeller, J., De Becker, D., Meert, A.-P., & Piccart-Gebhart, M. (2001). A clinical, pharmacokinetic and pharmacodynamic phase I study of the raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors. AACR-NCI-EORTC. Vol. 7 (p. 3768) (October 29 - November 2, 2001: Miami).
  10. 6. Awada, A., Burris, H. H., de Valeriola, D., Hendlisz, A., Huart, A., Gil, T., Crabeels, D., Moerman, C., Piccart-Gebhart, M., et al. (2001). Phase I clinical and pharmacology study of the novel epothilone analog BMS-247550 given weekly in patients advanced solid tumors. Clinical for Cancer Research. Vol. 7 (p. 3810) (2001).
  11. 7. Awada, A., Bleiberg, H., de Valeriola, D., Huart, A., Cornez, N., Piccart-Gebhart, M., et al. (2001). Phase I clinical and pharmacology study of the epothilone analog BMS-247550 given weekly in patients (pts) with advanced solid tumors. Proceedings of the American Society of Clinical Oncology. Vol. 20 (p. 108) (2001).
  12. 8. Hennebert, P., Biganzoli, L., Van Hoorebeeck, I., Awada, A., Coleman, R., Piccart-Gebhart, M., de Valeriola, D., et al. (2001). Pharmacokinetic phase I study of Caelyx in metastatic breast cancer patients. Proceedings of the Pharmacology and Molecular Mechanisms Group Winter Meeting of the EORTC (Janvier 2001: Verona, Italy)
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 39 Suivant >>